nmCRPC VL

The Impact of Advanced Imaging on Detection and Treatment in Nonmetastatic CRPC - Vahan Kassabian

Details
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel imaging techniques, particularly PSMA PET scans, have had an impact in diagnosing nmCRPC by identifying metastases not detected by traditional imaging. Dr. Kassabian highlights the importance of PSA kinetics in...

Navigating the Nuances: Exploring Imaging Options and Impact to Treatment Strategies in nmCRPC - Ryan Malone

Details
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease. The discussion covers landmark trials and their implications for treatment options, emph...

Delaying Time to Metastasis in Patients With High-Risk, M0 CRPC With Radiolabeled J591 Plus Ketoconazole and Hydrocortisone - Scott Tagawa

Details
Scott Tagawa joins Alicia Morgans to discuss a randomized phase II study on a salvage anti-PSMA radioimmunotherapy targeting non-metastatic CRPC population. The study enrolled patients with high-risk non-metastatic CRPC, defined as a PSA doubling time of less than eight months or an absolute PSA of at least 20, low testosterone, and non-metastatic as defined by no evidence of metastasis on CT or M...

mCRPC: Combining and Sequencing LUGPA 2022 Presentation - Evan Yu

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Evan Yu presented on metastatic castration-resistant prostate cancer (mCRPC) combining and sequencing. Biography: Evan Yu, MD , Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Clinical Research...

Progression Patterns by Types of Metastatic Spread, PSA, and Clinical Symptoms - Post-Hoc Analyses of ARAMIS - Alicia Morgans

Details
Neal Shore interviews Alicia Morgans about her poster presentation on the ARAMIS trial. The ARAMIS trial evaluated darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) patients with rising PSA levels and no radiographic evidence of disease. The study found that the combination of ADT and darolutamide extended metastasis-free survival by about two years and increased overall...

Genomic and Clinical Markers in nmCRPC APCCC 2022 Presentation - Joaquin Mateo

Details
Joaquin Mateo delivers a comprehensive talk on the challenges and opportunities of using genomic and clinical markers in non-metastatic castration-resistant prostate cancer (CRPC). Dr. Mateo emphasizes that while prognostic biomarkers can inform the likely course of the disease, there's currently no data to suggest that molecular profiling can improve patient outcomes in non-metastatic CRPC. He ar...

Optimizing Treatment for High-Risk M0CRPC - Laura-Maria Krabbe

Details
In a conversation between Alicia Morgans and Professor Laura-Maria Krabbe, they discuss the treatment of non-metastatic, castration-resistant prostate cancer (M0CRPC). They highlight the importance of identifying high-risk patients based on PSA doubling time and the need for treatment intensification in this population. They also mention the role of PSMA PET scans in determining the extent of dise...

Depression, Bone Health and Exercise in Prostate Cancer - Fred Saad, Tomasz Beer & Charles Ryan

Details
Alicia Morgans is joined by Drs Fred Saad, Charles Ryan, and Tomasz Beer at the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland, to discuss holistic treatment of men with prostate cancer who are being treated with ADT. Dr. Ryan discusses the lack of data on the treatment of depression in men on hormone therapy. Dr. Saad discusses the need to be aware of the patien...

Mental Health and Impact on Patients with GU Malignancies - Zachary Klaassen

Details
Zach Klaassen joins Alicia Morgans in discussing an underestimated topic of mental health and its effects on patients with genitourinary cancers. Drs. Klaassen and Morgans discuss hypothesis-generating population-level data in this landscape and talk through the importance of supporting these patients and using what Dr. Klaassen refers to as clinical intuition and asking follow-up questions when s...

Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk Nonmetastatic Prostate Cancer: STAMPEDE Platform Protocol, Journal Club- Christop...

Details
Christopher Wallis and Zachary Klaassen discuss the publication in the Lancet analyzing new data from the STAMPEDE trial of two randomized controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer. Biogr...